우리나라 성인 여성의 HPV 감염과 HPV 백신 접종에 대한 지식 및 태도 조사

키워드

참고문헌 (42)

1. Piasani P, "Cancer and infection: estimates of attributable fraction in 1990", Cancer Epidermiol Biomarkers and Prev, 6, pp.387~400 (1997)
2. Sankaranarayanan R, "An overview of cancer survival in developing countries", IARC Sci Publ, 145, pp.135~173 (1998)
3. Parkin DM, "Estimates of the worldwide incidence of 25 major cancer in 1990", Int J cancer, 80, pp.827~841 (1999)
4. Berkow R, "Merck Research Laboratories. The Merck manual of Medical information" (1997), Merck Research Laboratories
5. Hai-Rim Shin, "2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals", Cancer Research and Treatment, 36(2), pp.103~114 (2004), 대한암학회
6. Bosch FX, "The causal relation between human papillomavirus and cervical cancer", J Clin Pathol, 55, pp.244~265 (2002)
7. Bosch FX, "Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study Group", J Natl Cancer Inst, 87, pp.796~802 (1995)
8. Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J Pathol, 189, pp.12~19 (1999)
9. Bergeron C, "Human papillomaviruses associated with cervical intraepithelial neoplasia. Great diversity and distinct distribution in low- and high- grade lesion", Am J surg pathol, 16, pp.641~649 (1992)
10. Lungu O, "Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia", JAMA, 267, pp.2493~2496 (1992)
11. 박종섭, "한국 젊은 여성의 성생활 양상; HPV예방 백신 도입을 위한 예비 연구", Journal of Gynecologic Oncology, 18(3), pp.209~218 (2007), 대한부인종양학회
12. Stratton KR, "Vaccines for the 21st century : a tool for decisionmaking" (2000), National Academy Press
13. Garnertt GP, "The potential epidermiological impact of a genital herpes vaccine for women", Sex Transm Infect, 80, pp.24~29 (2004)
14. Taira AV, "Evaluating human papillomavirus vaccination programs", Emerg Infect Dis, 10, pp.1915~1923 (2004)
15. Goldie SJ, "Projected clinical benefits and cost-effectivemess of a human papillomavirus 16", 18 vaccine, 2004, pp.96, 604~615
16. Zimet GD, "Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control", Sex Transm Dis, 27, pp.49~52 (2000)
17. Han YJ, "Knowledge regarding cervical cancer, human papillomavirus and future acceptance of vaccination among girls in their late teens in Korea", Kor J Obstet Gynecol, 50, pp.1090~1099 (2007)
18. Glanz K, "Health behavior and health education : theory, research, and practice" (2002), Jossey-Bass
19. zur Hausen H, "Are human papillonavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix?", Int J cance, 63, pp.315~316 (1995)
20. Syrjänen KJ, "Spontaneous evolution of intraepithelial lesions according to the grade and type of implicated human papillomavirus (HPV)", Eur J Obstet Gynecol Reprod Biol, 65, pp.45~53 (1996)
21. Joo WD, "Prevalence of human papillomavirus infection in Korea women: risks of abnormal pap smears and cervical neoplasia", Kor J Gynecol Oncol, 15, pp.309~316 (2004)
22. Brown DR, "A longitudinal study of genital human papillomavirus infection in cohort of closely followed adolescent women", J Infect Dis, 191, pp.182~192 (2005)
23. Baseman JG, "The epidermiology of human papillomavirus infections", J Clin Virol, 32, pp.S16~S24 (2005)
24. Bekkers RL, "Epidermiological and clinical aspects of human papillomavirus defection in the prevention of cervical cancer", Rev Med Virol, 14, pp.95~105 (2004)
25. Harper DM, "Why am I scared of HPV?", CA Cancer J Clin, 54, pp.245~247 (2004)
26. Colmbo N, "The wider impact on women’s health. More than cervical cancer?", Eur J Obstet Gynecol Reprod Biol
27. Garnett GP, "Public health paradoxes and the epidermiological impact of an HPV vaccine", J Clin Virol, 19, pp.101~111 (2000)
28. Harper DM, "Efficacy of a bivalent L1 virus-like particle vaccine in preention of infection with human papillomavirsu type 16 and 18 in young women: a randomized controlled trial", Lancet, 364, pp.1757~1765 (2004)
29. Harper DM, "Sustained efficacy up to 4.5 years of bivalent L1 virus-like particle vaccine against human papillomavirus type 16 and 18: follow-up from randomized controlled trial", Lancet, 367, pp.1247~1255 (2006)
30. Koutsky LA, "A controlled trial of a human papillomavirus type 16 vaccine", N Engl J Med, 347, pp.1645~1651 (2002)
31. Villa LL, "Prophylatic quadrivalent human papillomavirus (type 6,11,16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase ∥ efficacy trial", Lancet Oncol, 6, pp.271~278 (2005)
32. Dell DL, "Knowledge about human papillomavirus among adolescents", Obstet Gynecol, 96(5), pp.653~656 (2000)
33. Moreira ED Jr, "Assessment of knowledge and attitudes of young uninsured women toward human papillomavirus vaccination and clinical trials", J Pediatr Adolesc Gynecol, 19, pp.81~87 (2006)
34. Brabin L, "Future acceptance of adolsent human papillomavirus vaccination: a survey of parental attitudes", Vaccine, 24, pp.3087~3094 (2006)
35. Lee PW, "Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong", Prev Med, 45, pp.130~134 (2007)
36. Sauvageau C, "Humam papillomavirus vaccine and cervical cancer screening accerptability among adults in Quecbed, Canada", BMC Public Health, 7, pp.304~ (2007)
37. Lenselink CH, "Parental acceptance of huma papillomavirus vaccines", Eur J Obstet Gynecol Reprod Biol, 137, pp.103~107 (2008)
38. Taylor JA, "Associations between parents’ preferences and perpection of barriers to vaccination and immunization status of their children: a study from Pediatric Research in Office Setting and the national Medical Association", Pediatrics, 110, pp.1110~1116 (2002)
39. Marshall H, "A cross-sectional survey to assess community attitude to introduction of Human papillomavirus vaccine", Aust N Z J Publid Health, 31, pp.235~242 (2007)
40. "Product approval information-liscensing action. Gardasil(Quadrivalent human papillomavirus type 6,11,16,18) Merk & Co"[URL]
41. Davis K, "Human papillomavirus vaccine acceptability among parents of 10-to 15-years-old adolescents", J Low Genit Tract Dis, 8, pp.188~194 (2004)
42. Noakes K, "Parental response to the introducing of a vaccine against human papilloma virus", Hum vaccine, 2, pp.243~248 (2006)

관련 논문AI추천